Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 39Lymphoma 34Lymphoma, Follicular 24Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 19Lymphoma, B-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Burkitt Lymphoma 14Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large-Cell, Anaplastic 8Glioma 8Neuroectodermal Tumors, Primitive, Peripheral 7Neuroblastoma 7Mycosis Fungoides 7Lymphoma, T-Cell 7Histiocytosis, Langerhans-Cell 7Wilms Tumor 6Waldenstrom Macroglobulinemia 6Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Lymphoma, T-Cell, Cutaneous 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Magnetic Resonance Spectroscopy × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡